| 生物活性 | Cardamonin can be found from cardamom, and target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibitmTOR,NF-κB,Akt,STAT3,Wnt/β-cateninandCOX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities[1][2]. |
体外研究
(In Vitro) | Cardamonin (5-40 μM, 24 or 48 h) treatment inhibits gastric cancer cell growth[3].
Cardamonin (10-30 μM, 24 or 48 h) treatment can regulate the expression of apoptosis relative protein[3].
Cardamonin (10-30 μM, 24 or 48 h) treatment can inhibit STAT3 phosphorylation[3].
Cardamonin (0-100 μM, 24 h) treatment improves the anti-oxidative capacity in HL-1 cells[4].
Cell Viability Assay[3] | Cell Line: | AGS, MGC-803, BGC-823 cells | | Concentration: | 5, 10, 20, 30, 40 μM | | Incubation Time: | 24 or 48 hours | | Result: | Inhibited cell growth in a concentration-dependent manner. |
Western Blot Analysis[3] | Cell Line: | AGS, MGC-803, BGC-823 cells | | Concentration: | 10, 20, 30 μM | | Incubation Time: | 24 or 48 hours | | Result: | Down-regulated Bcl-2, increased Bax protein expression, and increased the protein expression levels of Caspase-3. |
Western Blot Analysis[3] | Cell Line: | AGS cells | | Concentration: | 10, 20, 30 μM | | Incubation Time: | 24 or 48 hours | | Result: | Suppressed the phosphorylation level of STAT3. |
Western Blot Analysis[4] | Cell Line: | HL-1 cells | | Concentration: | 0, 25, 50, 100 μM | | Incubation Time: | 24 hours | | Result: | Showed anti-oxidant effects in doxorubicin-stimulated cardiomyocytes. |
|
体内研究
(In Vivo) | Cardamonin (oral gavage; 20, 40 or 80 mg/kg; once) treatments alleviates doxorubicin-induced cardiotoxicity and inhibits apoptosis in doxorubicin-challenged mice[4].
| Animal Model: | Male C57BL/6 J mice (8 weeks old, 20-22 g)[4] | | Dosage: | 20, 40 or 80 mg/kg | | Administration: | Oral gavage; 20, 40 or 80 mg/kg; once | | Result: | Rescued the reduction of LVEF% and LVFS% by doxorubicin, reduced the increasement of serum LDH, CK-MB and Tn-T levels by doxorubicin in a dose-dependent manner, improved doxorubicin-induced histological changes, and attenuated collagen accumulation in cardiac sections by doxorubicin in a dose-dependent manner. |
| Animal Model: | Male C57BL/6 J mice (8 weeks old, 20-22 g)[4] | | Dosage: | 20, 40 or 80 mg/kg | | Administration: | Oral gavage; 20, 40 or 80 mg/kg; once | | Result: | Rescued Bcl-2, and inhibited Bax and Caspase-3 cleavage in heart tissues from doxorubicin-challenged mice. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Zingiberaceae
- Boesenbergia rotunda
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 125 mg/mL(462.48 mM;Need ultrasonic) 配制储备液 | 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | | 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | | 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.17 mg/mL (8.03 mM); Clear solution
此方案可获得 ≥ 2.17 mg/mL (8.03 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com